Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

New Regeneron/Bayer Deal Builds On Eylea's Success

This article was originally published in Scrip

Executive Summary

Regeneron Pharmaceuticals Inc. and Bayer AG are building on a partnership that has borne fruit for nearly a decade with the March 24 announcement of a licensing agreement to create a successor product to Eylea (aflibercept).


Related Content

Regeneron Emphasizes Pipeline Promise As Eylea Pricing Pressure Builds